Form 4: ATAI Life Sciences Grants Over 130,000 Stock Options to Director and 10% Owner Christian Angermayer

ATAI Life Sciences N.V. has granted 131,698 stock options to Director and 10% owner Christian Angermayer, vesting over four years, tied to continued service and a voting agreement.

Summary

• On June 2, 2025, ATAI Life Sciences N.V. granted 131,698 stock options to Christian Angermayer, who serves as a Director and 10% owner of the company.
• The stock options have an exercise price of $2.49 per share.
• The options will vest over time, with 25% vesting on June 2, 2026, and the remaining portion vesting in 36 substantially equal monthly installments thereafter.
• The vesting is contingent upon Mr. Angermayer entering into an amended consultancy agreement, his continued service to the Issuer through each applicable vesting date, and Apeiron Investment Group Ltd.'s compliance with a Voting Agreement dated June 2, 2025, involving Beckley Psytech Limited, Atai Life Sciences N.V., and Apeiron Investment Group Ltd.
• The expiration date for these stock options is June 2, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key director and 10% owner is a positive signal for insider alignment and retention, indicating continued commitment. It is a standard compensation practice and not indicative of immediate financial distress or exceptional performance.

Positives

• The grant of stock options to a key director and 10% owner, Christian Angermayer, aligns his long-term incentives with the company's performance, potentially fostering greater commitment and strategic focus.
• Equity compensation is a standard method to retain and motivate key personnel, indicating the company's intent to secure Mr. Angermayer's continued service as a consultant.

Risks

• The vesting of the stock options is subject to specific conditions, including the reporting person entering into an amended consultancy agreement and Apeiron Investment Group Ltd.'s compliance with a voting agreement, which introduces conditional risk to the full realization of the grant.
• Failure to meet the specified conditions could result in a forfeiture of unvested options, potentially impacting the intended incentive.

Future Outlook

The stock option grant is intended to incentivize Christian Angermayer's continued service as a consultant and align his interests with the long-term success of ATAI Life Sciences N.V. through a multi-year vesting schedule.

Management Comments

• The Issuer granted stock options to the Reporting Person in further consideration of his continued service as a consultant and other valuable consideration.

Industry Context

This Form 4 filing details a routine equity compensation event for a director and significant shareholder within the biotechnology sector, specifically for ATAI Life Sciences, a company focused on psychedelic-based therapeutics. Such grants are common practice to align insider interests with company performance and retention.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation to directors and key consultants is a standard practice across the biotechnology and broader corporate landscape, aiming to align long-term interests.
• The vesting schedule, with an initial cliff and subsequent monthly installments over several years, is a common structure designed to ensure continued service and performance, comparable to similar arrangements seen in companies like Compass Pathways (CMPS) or MindMed (MNMD) within the psychedelic therapeutics space, or other early-stage biotech firms.

Corporate Governance

Related Party Transactions

• The grant of stock options to Christian Angermayer, a Director and 10% owner, constitutes a related party transaction.
• The vesting conditions reference a Voting Agreement involving Apeiron Investment Group Ltd. (likely affiliated with Mr. Angermayer), Beckley Psytech Limited, and Atai Life Sciences N.V., indicating a broader network of related party dealings influencing compensation.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a significant insider with long-term shareholder value through equity incentives.
• Employees: While not directly impacting all employees, this type of compensation sets a precedent for executive incentives and retention strategies.

Next Steps

• Christian Angermayer is expected to enter into an amended consultancy agreement with ATAI Life Sciences N.V.
• Christian Angermayer's continued service to the Issuer is required for the options to vest.
• Apeiron Investment Group Ltd. must comply with the Voting Agreement dated June 2, 2025, for the options to vest.
• The stock options will begin vesting on June 2, 2026, with subsequent monthly vesting installments.

Key Dates

Keywords

ATAI Life Sciences, ATAI, Stock Options, Christian Angermayer, Form 4, Insider Transaction, Equity Compensation, Director Compensation, Vesting Schedule, Biotechnology, Psychedelics